Intravenous Thyroxine for Heart-Eligible Organ Donors
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 838 participants.
Also called NCT04415658
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 838 participants
- Registry
-
NCT04415658
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04415658. Randomized; no masking; primary purpose treatment. Start 2020-12-01 (actual); primary completion 2022-11-06 (actual). Results posted on 2024-01-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intravenous Thyroxine for Heart-Eligible Organ Donors
- Condition
- Brain Death
- Condition
- Heart Failure
- Intervention (Drug)
- Thyroxine
- Intervention (Drug)
- Saline
- Lead sponsor
- Washington University School of Medicine
- Collaborator
- Mid-America Transplant
Record details
- Record id
cardio:ct-nct04415658- Content hash
a6f4d97874268bc0dddeaf7e91b83ff9156fd6ab836e89fe9abfb978db70e0ee